BlueRock Therapeutics LP
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BlueRock Therapeutics LP
Bayer pharma research head Christian Rommel has told Scrip he was excited about the Phase I data on Parkinson's disease prospect bemdaneprocel, which is comprised of dopamine-producing neurons derived from pluripotent stem cells, but also advocated caution at this early stage.
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
The German company’s two top sellers are marketed by partners in the US, but Bayer will pocket all US sales from its four newest products, at a time when pressures are mounting at home and abroad.
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Blue Rock Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.